VANCOUVER, Canada I April 29, 2025 I AbCellera (Nasdaq: ABCL) today announced new data on its PSMA x CD3 T-cell engagers (TCEs), presented as a poster at the ...

MARSEILLE, France I April 29, 2025 I Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“Innate” or the “Company”) today shared new preclinical data for ...

AI-designed oligos with goal of making therapies safer and more effective for patients with rare and common diseases ...

BASEL, Switzerland I April 29, 2025 I Sandoz (SIX:SDZ/OTCQX:SDZNY), the global leader in generic and biosimilar medicines, announced today that it has signed ...

Findings demonstrate ATYR2810’s anti-tumor activity and increased survival in a model of glioblastoma multiforme (GBM), a primary form of brain cancer.

TAIPEI, Taiwan I April 29, 2025 I AP Biosciences, a clinical-stage biopharmaceutical company dedicated to transforming cancer therapy through innovative ...

WHIPPANY, NJ, USA I April 29, 2025 I Bayer announced today initiation of a Phase I clinical trial with 225Ac-GPC3 (BAY 3547926), an investigational targeted ...

Proof-of-concept shows mRNA genetic circuitry able to target expression of IL-12 to tumors when systemically delivered ...

VYJUVEK was approved by the FDA in the United States in May 2023 and is also under review for approval by Japan’s Pharmaceuticals and Medical Devices Agency with a decision expected in 2H 2025.

Lead development candidate, AMP-410, leverages proprietary Ampersand technology to block VEGF and allosterically activate 4-1BB signaling – unlike traditional ...

Approval of Lynozyfic is based on data showing deep and durable responses in relapsed/refractory multiple myeloma ...

NEW YORK, NY, USA I April 28, 2025 I IN8bio, Inc. (Nasdaq: INAB), a clinical-stage biopharmaceutical company developing innovative gamma-delta (γδ) T cell ...